Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m&lt;sup&gt;6&lt;/sup&gt;A modification of LINC01579 and suppressing IL-17/NF-κB signaling. This evidence concerns the gene IL17A and ankylosing spondylitis.